How long you stay on Lupron for prostate cancer depends almost entirely on your cancer’s stage and risk level. For localized disease treated with radiation, standard courses run 6 to 24 months. For metastatic disease, treatment is typically continuous and indefinite. There is no hard maximum set by the drug itself, but the longer you’re on it, the more cumulative side effects you’ll face, which is why oncologists match duration carefully to how aggressive the cancer is.
Duration Based on Cancer Stage
For men with intermediate-risk prostate cancer receiving radiation therapy, the typical Lupron course is about 6 months. For high-risk localized disease, guidelines call for 18 to 36 months. A large clinical trial comparing 6 months versus 24 months of hormone therapy alongside post-surgical radiation found that the longer course reduced the 10-year rate of cancer spreading to distant sites: 78.1% of men in the 24-month group remained metastasis-free at 10 years, compared to 71.9% in the 6-month group. Overall survival was similar between the two groups, though, which means the decision often comes down to whether the benefit in delaying spread is worth the extra time on treatment.
For metastatic prostate cancer that still responds to hormone therapy, Lupron is given continuously with no planned stopping point. The American Urological Association advises against intermittent (on-and-off) hormone therapy for men with metastatic disease, based on a major trial that showed a nonsignificant survival advantage for continuous treatment. Current practice also layers additional medications on top of Lupron for metastatic disease, since Lupron alone is no longer considered sufficient.
One exception: if hormone therapy was started for a rising PSA after surgery (biochemical recurrence) without evidence of visible metastases, intermittent therapy may be offered. In that scenario, you’d cycle on and off treatment, with your PSA levels guiding when to restart.
How Intermittent Therapy Works
Intermittent schedules vary. Some protocols use one month on and one month off, others use one month on and two months off, and some alternate three months on with three months off. The goal is to give your body breaks from testosterone suppression while keeping the cancer controlled. During off periods, your oncologist monitors PSA levels, and treatment restarts when PSA rises above a certain threshold. This approach can reduce the burden of side effects during the off-cycle months, though it’s only appropriate for non-metastatic situations.
Injection Schedule Options
Lupron comes in four formulations that differ by how often you need an injection, not by how long your overall treatment lasts. The options are every 4 weeks (7.5 mg), every 12 weeks (22.5 mg), every 16 weeks (30 mg), or every 24 weeks (45 mg). All of them suppress testosterone to castrate levels in roughly 94% to 95% of men within the first month. The six-month formulation maintained suppression through 48 weeks in about 93% of patients in clinical testing. Your doctor will choose the interval based on convenience and how well your testosterone stays suppressed. Missing or delaying injections can allow testosterone to creep back up, so staying on schedule matters regardless of which formulation you’re on.
When Lupron Stops Working
Lupron doesn’t work forever. Over time, prostate cancer cells can adapt and grow even with very low testosterone levels, a stage called castration-resistant prostate cancer. The median time to reach this point is 18 to 24 months, though individual variation is enormous. Men whose PSA responds well to initial treatment can remain sensitive to Lupron for nearly 8 years, while those with a poor early PSA response may progress in as little as 18 months. Even after the cancer becomes castration-resistant, most men continue Lupron as a backbone while adding other treatments, because allowing testosterone to rebound could accelerate growth further.
Cumulative Side Effects Over Time
The longer you stay on Lupron, the more its side effects compound. Bone loss is one of the most significant concerns. Bone mineral density drops 2% to 4% per year on treatment, and fracture rates climb from about 5% at 22 months to 28% at 7 years. If you’re on long-term therapy, your care team should monitor your bone density and may recommend supplements or bone-protective medications.
Cardiovascular risk also increases. Lupron raises cholesterol, blood pressure, and blood sugar, and shifts body composition toward more fat and less muscle. One clinical trial projected a major cardiovascular event rate of about 10% over 12 months in men on leuprolide (Lupron), and observational studies have consistently linked hormone therapy with higher cardiovascular illness and death, particularly in men who already have heart disease risk factors. Managing blood pressure, cholesterol, and blood sugar becomes an active part of your care while you’re on treatment.
The 24-month course studied alongside radiation did carry more grade 3 to 4 side effects than the 6-month course: 19% versus 14%. The most common serious complications were urethral narrowing and blood in the urine, driven partly by the radiation rather than the hormone therapy alone.
Testosterone Recovery After Stopping
If you do stop Lupron, testosterone doesn’t bounce back immediately, and for some men it never fully returns. Research from Memorial Sloan Kettering found that average testosterone levels gradually climbed after stopping treatment: roughly 216 ng/dL at 6 to 12 months post-cessation, 275 ng/dL at 12 to 18 months, and 321 ng/dL beyond 24 months. Normal is generally above 300 ng/dL.
About one-quarter of men in that study never reached normal testosterone levels within two years, and one in ten remained at castrate levels (below 50 ng/dL) even two years after their last injection. Two factors made poor recovery more likely: being on Lupron for longer than six months, and having a baseline testosterone below 400 ng/dL before starting treatment. Men who had been on treatment longer than six months had four times the odds of remaining at castrate levels compared to those with shorter courses. This is worth factoring in when weighing a longer treatment duration, especially if quality of life concerns like fatigue, sexual function, and body composition matter to you.
Monitoring While on Treatment
PSA blood tests are the primary way your oncologist tracks whether Lupron is still controlling the cancer. These are typically done every few months. Testosterone levels should also be checked regularly to confirm the drug is actually suppressing production, though in practice testosterone is monitored less frequently than PSA. Ensuring testosterone stays below 50 ng/dL throughout treatment is important, because incomplete suppression can undermine the therapy’s effectiveness. If your testosterone isn’t staying low enough, your doctor may adjust the formulation, shorten the interval between injections, or switch to a different medication.